Home Press Releases Transthyretin Amyloidosis Treatment Market Size Worth $8.81 Billion By 2030 | CAGR: 7.47%

Transthyretin Amyloidosis Treatment Market Size Worth $8.81 Billion By 2030 | CAGR: 7.47%

The transthyretin amyloidosis treatment market size is expected to reach USD 8.81 billion by 2030, according to a new study by Polaris Market Research. The report “Transthyretin Amyloidosis Treatment Market Share, Size, Trends, Industry Analysis Report, By Type (ATTR-PN, ATTR-CM); By Therapy; By Disease Type; By Distribution Channel; By Region; Segment Forecast, 2022 – 2030” gives a detailed insight into current market dynamics and provides analysis on future market growth.

 

The rising number of geriatrics in the patient population and an increasing number of geriatrics developing chronic disorders are anticipated to drive the growth of transthyretin amyloidosis treatment. Since transthyretin amyloidosis treatment is expensive, adopting this therapy is higher in high-income regions in developing economies.

 

Moreover, the market is estimated to increase the influx of pipeline drugs in lieu of active investments by leading players in developing these drugs, thereby augmenting the growth of its treatment market. The increasing awareness of treating this disease by physicians and key market players, along with support provided by government aids to improve the adoption of these novel therapies, is expected to drive the growth of the market.

 

Have Questions? Request a sample or make an Inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/transthyretin-amyloidosis-treatment-market/request-for-sample

 

Transthyretin amyloid cardiomyopathy (ATTR-CM) is an under-diagnosed condition causing heart failure in older adults. It is a type of systemic amyloidoses disorder caused by an accumulation of a protein that forms amyloid fibrils in several tissues. The condition is a silent cause of deteriorating organ health and may prove fatal if undiagnosed. Some factors causing this condition are co-relation with its hereditary nature, unhealthy food habits and a sedentary lifestyle. This coupled with the rising prevalence of the disease, is anticipated to drive the growth of this segment owing to the increasing patient population diagnosed with this disease.

 

Transthyretin amyloidal polyneuropathy (ATTR-PN), however, is a separate condition originating from a similar pathophysiology that affects the nervous system and results in multiple organ failures as the disease progresses due to nerve damage. Major market players developing key drugs to manage and treat this condition, along with regulatory approvals granted by government regulatory bodies to improve product reach across high-income countries owing to higher healthcare expenditure, are anticipated to drive the growth of this segment. The market growth is also driven owing to consistent clinical trials conducted by various academic and research institutes developing pipeline drugs with promising results.

 

Transthyretin Amyloidosis Treatment Market Report Highlights

  • ATTR-CM segment is anticipated to grow at a high CAGR over the forecast period owing to the rising incidence of the condition among patients suffering from cardiomyopathy along with better availability of treatment options for the segment.
  • Targeted therapy accounted major revenue share, which is accelerated by the increasing applications alongside a large number of trials and studies proving its effective treatment owing to the complex nature of transthyretin amyloidosis as a disease.
  • Hereditary transthyretin amyloidosis is expected to hold a significant market share over the forecast period due to the increasing patient pool suffering from the condition, along with awareness campaigns conducted by key government organizations.
  • North America is expected to grow dominantly over the projected period because of the strategic presence of key companies and research institutions expediting the availability of treatment in the region.
  • The global players include Pfizer, Johnson & Johnson Services, Ionis Pharmaceuticals, Alnylam Pharmaceuticals, BridgeBio Pharma.

 

Polaris Market Research has segmented the Transthyretin Amyloidosis Treatment market report based on type, therapy, disease type, distribution channel and region:

 

Transthyretin Amyloidosis Treatment, Type Outlook (Revenue – USD Billion, 2018 – 2030)

  • ATTR-CM
  • ATTR-PN

Transthyretin Amyloidosis Treatment, Therapy Outlook (Revenue – USD Billion, 2018 – 2030)

  • Targeted Therapy
  • Supportive Therapy
  • Pipeline Therapy

Transthyretin Amyloidosis Treatment, By Disease Outlook (Revenue – USD Billion, 2018 – 2030)

  • Hereditary transthyretin amyloidosis
  • Wild type transthyretin amyloidosis

Transthyretin Amyloidosis Treatment, By Distribution Channel Outlook (Revenue – USD Billion, 2018 – 2030)

  • Hospital Pharmacy
  • Online Pharmacy

Transthyretin Amyloidosis Treatment, Regional Outlook (Revenue – USD Billion, 2018 – 2030)

  • North America
    • U.S
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Russia
    • Netherlands
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Indonesia
    • Malaysia
  • Latin America
    • Argentina
    • Brazil
    • Mexico
  • Middle East & Africa
    • UAE
    • Saudi Arabia
    • Israel
    • South Africa

License and Pricing

Buy Now

Purchase Report Sections

  • Regional analysis
  • Segmentation analysis
  • Industry outlook
  • Competitive landscape
Request for Discount Pricing

Request For Customization

Please specify your research requirement and get customized report


Regional AnalysisSegmentation AnalysisIndustry OutlookCompetitive Analysis
By using this form you agree with the storage and handling of your data by this website.

Speak to Analyst

By using this form you agree with the storage and handling of your data by this website.